🔗 Share this article

Given that the United States undertakes historic changes to its vaccination schedules, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a Danish American physician and public health researcher who initially gained attention by questioning COVID-19 vaccines during the pandemic and has focused upon potential deaths after Covid vaccination in her short time at the FDA.

Planned Overhauls to Childhood Vaccine Program

Public health authorities were set to announce radical revisions to the pediatric vaccination calendar earlier this month, synchronizing the US with the Danish vaccine program, sources say – a major change that would place the US at odds with much of the global community with little proof for improved outcomes. The announcement has been postponed until the coming year.

Instead of Vinay Prasad, Høeg is listed to speak at the event. She was recently named temporary leader of the FDA’s CDER, the fifth person to head the division this year.

A New Direction at the Regulatory Body

The acting appointment may indicate a closer partnership between the drug and vaccine branches as Høeg and Prasad consolidate power at the FDA – and it suggests a greater focus upon reevaluating long-standing vaccines at the FDA.

The new acting director has often pushed for discontinuing certain childhood immunization guidelines in the US so as to align more like the Danish model, a country with comprehensive healthcare and a citizenry about the population of the state of Wisconsin.

To date comments, she has kept her attention on vaccination policy – typically the responsibility of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Background

The appointee has no obvious background in drug development, oversight or leadership, which has been customary for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a clinical trial. She lacks experience in leading a sizeable institution. She is not an expert in pharmaceutical oversight.”

Former heads of the center would “be deeply familiar with laws and regulations and the research of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she has not acquired the kind of background that former directors who led the center have had.”

The drug center has an immense workload at the FDA, Woodcock pointed out.

“Many people just pays attention on the novel medication approvals, but the generic drug division approves numerous generic medications. There is also a biosimilars division, non-prescription drug unit and other areas, and each of these need to be supervised,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial leadership component to the position, which supervises in excess of 5,000 personnel. “It is a enormous leadership role, if you do it right,” Woodcock added.

Response and Disputed Programs

When asked about concerns about Dr. Høeg's qualifications and whether this assignment represents more teamwork among agency officials on vaccines, a spokesperson responded that the “questions rely on inaccurate premises”.

“Her resume aligns with the functions of her role,” the representative stated, noting the time Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg inherits the commissioner’s new priority voucher program, a controversial one-day medication authorization process that allegedly worried her preceding directors. “How are these medications being selected for this expedited pathway? Who makes the choices?” Howard questioned. “There is a lot of lack of transparency occurring at the agency right now.”

Overall, he stated, “the agency seems to be moving towards laxer regulations of all drugs, with the exception of shots.”

Established Track Record on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if troubling, track record, Howard observe. She released a study using non-validated volunteer-provided data to estimate the incidence of myocarditis after COVID-19 immunization. She advised the Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the new government included revising guidelines for novel immunizations and discontinuing “optional” vaccines, she stated after the election on a online show. At the FDA, Dr. Høeg has reportedly floated the idea of excluding young men from obtaining Covid vaccines.

“She is an all-around true believer who commences with her beliefs and works backwards to fit the science in a very deceptive, fraudulent manner,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg joined fellow dissenters, {like|